Coronary CTA is a low cost, non-invasive alternative for evaluating coronary artery disease

Coronary CTA offers a low cost, non-invasive alternative to conventional angiography for evaluating patients who are suspected of having coronary artery disease; true even if the patients have calcified coronary artery plaques, according to a study performed at the Thomas Jefferson University Hospital, Philadelphia, PA.

The study included 31 patients who had one or more calcified coronary artery plaques that were discovered during coronary CTA. Calcified plaques in the arteries were graded as small, moderate or large. Initially the accuracy rate of determining the degree of stenosis caused by the larger calcified plaques was 67%. The study is ongoing and "now with further experience, the accuracy rate of determining the degree of stenosis with larger plaques is 72%," said David C. Levin, MD, lead author of the study.

"Patients who have calcified plaques in their coronary arteries can be evaluated accurately using coronary CTA. The procedure is non-invasive, cheaper and does not require hospitalization. Using coronary CTA you can look at a patient's arteries from an infinite number of angles and look at cross sections of vessels. With conventional angiography, the patient usually is admitted to the hospital and the arteries are only visible from 7 to 10 different angles," said Dr. Levin.

Coronary CTA is recommended for patients with an intermediate risk of coronary artery disease. "A good candidate is somebody who has an atypical chest pain pattern; chest pain that comes and goes during the day, night, exercise, rest etc. Family history, high cholesterol, diabetes, smoking and hypertension also play a big factor in the determining risk category," said Dr. Levin.

This study appears in the December issue of the American Journal of Roentgenology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease